Pharmaco-economic evaluation of universal HIV-screening of pregnant women; a cost-effectiveness analysis for Amsterdam;Farmaco-economische evaluatie van universele HIV-screening in de zwangerschap; een kosteneffectiviteitsanalyse voor Amsterdam

Nederlands Tijdschrift voor Geneeskunde

Volumn 144, Issue 16, 2000, Pages 749-754

  Postma, M J ^a   Van Den Hoek, J A R ^b   Beck, E J ^c   Heeg, B ^a   Jagek, J C ^d   Coutinho, R A ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; ARTIFICIAL MILK; BOTTLE FEEDING; CESAREAN SECTION; COST EFFECTIVENESS ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL DISEASE; NETHERLANDS; PREGNANCY; PRENATAL CARE; PREVALENCE; SCREENING;

ADULT; COST-BENEFIT ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MASS SCREENING; NETHERLANDS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VALUE OF LIFE;

EID: 0034655617     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Coutinho RA, Hoogkamp-Korstanje JAA, Danner SA, Therapeutische mogelijkheden bij HIV-infectie nopen tot verruiming van het HIV-testbeleid. Ned Tijdschr Geneeskd 1999;143:598-9.
2. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 - a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;340:977-87.
3. Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992;340:585-8.
4. Hock JAR van den, Mulder-Folkerts DKF, Dukers NHTM, Fennema JSA, Coutinho RA. Surveillance van aids en HIV-infectie in Amsterdam, 1997. Ned Tijdschr Geneeskd 1998;142:2861-5.
5. Postma MJ, Beck EJ, Mandalia S, Sherr L, Walters MDS, Houweling H, et al. Universal HIV screening of pregnant women in England: cost effectiveness analysis. BMJ 1999;318:1656-60.
6. Bindels PJE, Mulder-Folkerts DKF, Boer K, Schutte MF, Velde WJ van de, Wong FJ, et al. The FIIV prevalence among pregnant women in the Amsterdam region (1988-1991). Eur J Epidemiol 1994;10:331-8.
7. Sculpher MJ, Gibb D, Ades AE, Ratcliffe J, Duong T, Modelling the costs of paediatric HIV infection and AIDS: comparison of infected children born to screened and unscreened mothers. AIDS 1998;12: 1371-80.
8. Ziekenfondsraad. Diagnostisch kompas 1997. Amstelveen: Ziekenfondsraad: 1997.
9. Ziekenfondsraad. Farmacotherapeutisch kompas 1999. Amstelveen: Ziekenfondsraad: 1998.
10. Rutten FFH, Ineveld BM van, Ommen R van, Hout BA van, Huijsman R. Kostenberekening bij gezondheidszorgonderzoek: richtlijnen voor de praktijk. Utrecht: Van Arkel: 1993.
11. Postma MJ. Assessment of the economic impact of AIDS at national and multi-national level [proefschrift]. Maastricht: Universiteit Maastricht; 1998.
12. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press: 1998.
13. Ministerie van Financiën. Handhoek Financiële Informatie en Administratie Rijksoverheid (HAFIR). Den Haag: Ministerie van Financiën: 1996.
14. Jefferson T, Demicheli V, Mugford M. Elementary economic evaluation in health care. Londen: BMJ Publishing Group: 1996.
15. Parsonage M, Neuburger H. Discounting and health benefits. Health Econ 1992;1:71-6.
16. Postma MJ, Bergen JEAM van, Jager JC. Pharmaco-economic evaluation of antiretrovirals in treatment and prevention of HIV/AIDS. Proceedings 12th World AIDS Conference. Part II. Clinical science. Bologna: Monduzzi Editore SpA: 1998, p. 381-5.
17. Petrou S, Dooley M, Whitaker L, Beck E, Kupek E, Wadsworth J, et al. The economic costs of caring for people with HIV infection and AIDS in England and Wales. PharmacoEconomics 1996;4:332-40.
18. Gezondheidsraad. Beraadsgroep Infectie en immuniteit. Herziening van het HIV-testbeleid. Publicatienr 1999/02. Den Haag: Gezondheidsraad: 1999.
19. Postma MJ, Bos JM, Gennep M van, Jager JC, Baltussen R, Sprenger MJW. Economic evaluation of influenza vaccination; assessment for the Netherlands. PharmacoEconomics 1999;16(Suppl 1):33-40.